隆平高科(000998) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was -292,769,848.93 CNY, a decrease of 55.99% compared to the same period last year[3]. - The net profit attributable to shareholders was -241,166,494.47 CNY, representing an increase of 9.38% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -599,019,467.46 CNY, a decrease of 90.55% compared to the same period last year[3]. - Total operating revenue for Q3 2021 was CNY 827,047,303.99, a decrease of 12.4% compared to CNY 944,093,446.42 in the same period last year[16]. - Net profit for Q3 2021 was a loss of CNY 276,206,763.07, compared to a loss of CNY 300,720,168.91 in the previous year[17]. - The total comprehensive income attributable to the parent company was -388,803,580.42 CNY, compared to -492,478,843.70 CNY in the previous period, showing an improvement of approximately 21.1%[18]. - The company’s basic and diluted earnings per share were both -0.2305 CNY, compared to -0.2625 CNY in the previous period, indicating a reduction in losses[18]. Assets and Liabilities - The total assets at the end of the reporting period were 14,162,701,904.93 CNY, an increase of 2.25% from the end of the previous year[3]. - The company's total assets reached CNY 14,162,701,904.93, an increase from CNY 13,850,860,795.49 in the previous year[15]. - Total liabilities amounted to CNY 8,184,819,079.68, up from CNY 7,562,604,877.76 year-over-year[15]. - Total non-current assets amounted to CNY 7,761,264,874.29, a decrease of CNY 11,632,623.69 compared to the previous period[23]. - Total assets reached CNY 13,850,860,795.49, reflecting a decrease of CNY 11,632,623.69 from the previous period[24]. - Current liabilities totaled CNY 4,617,987,832.39, remaining unchanged from the previous period[24]. - Long-term borrowings were reported at CNY 2,863,562,690.00, consistent with the previous period[24]. - Total equity attributable to shareholders of the parent company decreased to CNY 5,260,628,575.11 from CNY 5,510,651,560.96[15]. Cash Flow - The company reported a cash flow from operating activities of 603,568,568.69 CNY, which decreased by 12.28% year-to-date[3]. - The net cash flow from operating activities was 603,568,568.69 CNY, a decrease of 12.3% from 688,076,561.58 CNY in the previous period[20]. - Cash inflow from operating activities totaled 2,363,174,908.31 CNY, up 12.1% from 2,108,607,286.61 CNY year-on-year[20]. - The company reported a net cash outflow from investing activities of -646,073,432.44 CNY, worsening from -333,264,331.03 CNY in the previous period[21]. - The cash flow from financing activities resulted in a net outflow of -459,677,176.87 CNY, an improvement from -705,933,428.44 CNY in the previous period[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 94,357[8]. - The largest shareholder, CITIC Agricultural Technology Co., Ltd., holds 16.54% of the shares[8]. Inventory and Impairment - The company recorded a provision for inventory impairment of 193 million CNY during the reporting period due to inventory checks[7]. - The company’s inventory as of September 30, 2021, was approximately CNY 2.45 billion, slightly down from CNY 2.47 billion at the end of 2020, a decrease of about 0.5%[13]. Investments and Equity - The company recognized non-recurring gains of 404,644,359.73 CNY from the disposal of non-current assets, primarily from the transfer of partial equity in Longping Biotechnology (Hainan) Co., Ltd.[5]. - The company completed a share transfer of 28.48% in Longping Biology for CNY 28.48 million, reducing its stake from 52.34% to 18.13%[11]. - The company received a total of CNY 28.48 million from the share transfer to the central enterprise fund, with the second payment of CNY 13.95 million received on August 17, 2021[11]. - The company’s long-term equity investments increased to approximately CNY 2.35 billion from CNY 2.20 billion, showing a growth of about 6.7%[13]. Research and Development - Research and development expenses for the quarter were CNY 109,201,266.15, an increase from CNY 75,251,160.96 in the same period last year[16]. Regulatory and Approval Status - The company’s non-public offering application was not approved by the China Securities Regulatory Commission on October 14, 2021[11]. - The third quarter report was not audited, indicating that the figures may be subject to change upon final review[26].